- Home
- ASC vs SVRA Comparison
ASC vs SVRA Comparison
Compare ASC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- SVRA
- Stock Information
- Founded
- ASC 2010
- SVRA 2007
- Country
- ASC Bermuda
- SVRA United States
- Employees
- ASC N/A
- SVRA N/A
- Industry
- ASC Marine Transportation
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- SVRA Health Care
- Exchange
- ASC Nasdaq
- SVRA Nasdaq
- Market Cap
- ASC 399.7M
- SVRA 433.8M
- IPO Year
- ASC 2013
- SVRA N/A
- Fundamental
- Price
- ASC $10.22
- SVRA $2.58
- Analyst Decision
- ASC Buy
- SVRA Buy
- Analyst Count
- ASC 3
- SVRA 5
- Target Price
- ASC $13.67
- SVRA $5.60
- AVG Volume (30 Days)
- ASC 555.9K
- SVRA 1.3M
- Earning Date
- ASC 07-30-2025
- SVRA 08-11-2025
- Dividend Yield
- ASC 9.30%
- SVRA N/A
- EPS Growth
- ASC N/A
- SVRA N/A
- EPS
- ASC 2.30
- SVRA N/A
- Revenue
- ASC $373,479,000.00
- SVRA N/A
- Revenue This Year
- ASC N/A
- SVRA N/A
- Revenue Next Year
- ASC N/A
- SVRA N/A
- P/E Ratio
- ASC $4.49
- SVRA N/A
- Revenue Growth
- ASC N/A
- SVRA N/A
- 52 Week Low
- ASC $8.32
- SVRA $1.89
- 52 Week High
- ASC $22.70
- SVRA $4.74
- Technical
- Relative Strength Index (RSI)
- ASC 53.07
- SVRA 59.80
- Support Level
- ASC $9.90
- SVRA $2.25
- Resistance Level
- ASC $10.53
- SVRA $2.39
- Average True Range (ATR)
- ASC 0.30
- SVRA 0.15
- MACD
- ASC 0.01
- SVRA 0.04
- Stochastic Oscillator
- ASC 54.55
- SVRA 88.61
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.